brentuximab vedotin,nivolumab
seagen,takeda,bms
['lymphoma', 'brentuximab', 'hodgkin', 'cml', ' vedo', 'seagen', 'takeda']
brentuximab vedotin + immunotherapy shows 98% orr and 93% cr in patients with early-stage classical hodgkin lymphoma #adc #17icml #lymphoma #oncology #hematology
Onco’Zine reports about current research and development in hematology and oncology.